In an older adult with Alzheimer’s disease who is acutely agitated and has no evidence of infection, what intramuscular antipsychotic and dosing is recommended?

Intramuscular Antipsychotic for Acute Agitation in Alzheimer's Disease

For an older adult with Alzheimer's disease presenting with acute agitation without infection, use intramuscular haloperidol 0.5-1 mg as the first-line agent, with the option to repeat every 1-2 hours as needed, using lower doses (0.25-0.5 mg) in frail or elderly patients.

Rationale and Evidence Base

The 2002 American Family Physician guidelines specifically address Alzheimer's disease and recommend starting with risperidone 0.25 mg per day or olanzapine 2.5 mg per day for behavioral symptoms, but these are oral formulations 1. However, for acute agitation requiring intramuscular administration, the evidence supports different agents.

First-Line IM Options

Haloperidol remains the most evidence-supported IM antipsychotic for acute agitation across multiple guidelines:

• Starting dose: 0.5-1 mg IM 2
• Elderly/frail patients: 0.25-0.5 mg IM 2
• Can be repeated every 1-2 hours as needed 2
• Has the strongest evidence base among conventional antipsychotics 3

Alternative IM Atypical Antipsychotics

If you prefer an atypical antipsychotic due to lower extrapyramidal symptom (EPS) risk:

Olanzapine IM:

• Dose: 2.5-5 mg IM 2
• Reduce to 2.5 mg in elderly patients 2
• Research specifically in dementia-related agitation shows 5 mg IM olanzapine was effective at 2 hours and maintained superiority over placebo at 24 hours 4
• Lower EPS risk than haloperidol 4, 5
• Caution: Risk of oversedation and respiratory depression when combined with benzodiazepines 2

Aripiprazole IM:

• Dose: 5 mg IM (can divide into 2.5 mg doses given 2 hours apart) 2
• Research in dementia patients showed 10-15 mg total dose (divided) was safe and well-tolerated 6
• Onset of efficacy may be delayed (45-90 minutes) compared to other agents 7

Critical Safety Considerations

Black Box Warning

All antipsychotics carry an FDA black box warning for increased mortality risk in elderly patients with dementia-related psychosis. This must be discussed with the patient (if feasible) and surrogate decision maker before administration 8.

Specific Risks in Alzheimer's Patients

Avoid haloperidol if:

• Patient has Parkinson's disease or Lewy body dementia (high EPS risk) 2
• Prolonged QTc interval on baseline ECG 2

Monitor for:

• Extrapyramidal symptoms (especially with haloperidol) 2, 1, 2
• Orthostatic hypotension (all agents) 2, 1, 2
• Oversedation (especially olanzapine) 2, 5
• Paradoxical agitation (can occur with any agent) 2

Dosing Adjustments

Reduce doses by 50% in:

• Frail elderly patients 2
• Hepatic impairment (olanzapine, aripiprazole) 2
• Renal impairment with eGFR <30 mL/min (avoid morphine-based sedatives; use oxycodone equivalent if needed for severe agitation) 9

When to Add or Switch Agents

If haloperidol alone is insufficient after 30-60 minutes:

• Consider adding lorazepam 0.5-1 mg IM (reduce to 0.25-0.5 mg in elderly) 9
• The combination may produce more rapid sedation than monotherapy 3
• Caution: Increased fall risk and potential for delirium with benzodiazepines 2

If patient remains severely agitated:

• Midazolam 0.5-1 mg IM (elderly dose) can be used as crisis medication 2
• Standard dose is 2.5-5 mg IM, but use lower range in elderly 2

Common Pitfalls to Avoid

1. Do not use typical antipsychotics as first-line in Lewy body dementia or Parkinson's disease dementia - they will cause severe EPS 2

2. Do not combine high-dose olanzapine with benzodiazepines - fatalities have been reported 2

3. Do not use anticholinergic agents (benztropine, trihexyphenidyl) to treat EPS in dementia patients - they worsen cognition and delirium 1

4. Do not continue antipsychotic beyond acute crisis without reassessment - if no response after 4 weeks at adequate dose, taper and discontinue 8

5. Always rule out reversible causes first - pain, urinary retention, constipation, hypoxia 9

Practical Algorithm

1. Assess for reversible causes (pain, retention, constipation, hypoxia)
2. Attempt verbal de-escalation first
3. If IM medication required:
   • Standard choice: Haloperidol 0.5-1 mg IM (0.25-0.5 mg if frail/elderly)
   • If EPS concern or preference for atypical: Olanzapine 2.5-5 mg IM (2.5 mg if elderly)
   • If both unavailable: Aripiprazole 5 mg IM
4. Reassess at 30-60 minutes
5. If inadequate response: Repeat dose or add lorazepam 0.25-0.5 mg IM (elderly dose)
6. Monitor vital signs, sedation level, and EPS for 2-4 hours

The 2018 ESMO guidelines provide the most comprehensive and recent dosing recommendations for elderly patients with agitation 2, while the 2016 APA guideline emphasizes the importance of risk-benefit discussion and time-limited use in dementia patients 8.